These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 36841635)

  • 1. Fragment-based drug discovery supports drugging 'undruggable' protein-protein interactions.
    Wang ZZ; Shi XX; Huang GY; Hao GF; Yang GF
    Trends Biochem Sci; 2023 Jun; 48(6):539-552. PubMed ID: 36841635
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging roles of allosteric modulators in the regulation of protein-protein interactions (PPIs): A new paradigm for PPI drug discovery.
    Ni D; Lu S; Zhang J
    Med Res Rev; 2019 Nov; 39(6):2314-2342. PubMed ID: 30957264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Computational methods-guided design of modulators targeting protein-protein interactions (PPIs).
    Qiu Y; Li X; He X; Pu J; Zhang J; Lu S
    Eur J Med Chem; 2020 Dec; 207():112764. PubMed ID: 32871340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Computational approaches for the design of modulators targeting protein-protein interactions.
    Rehman AU; Khurshid B; Ali Y; Rasheed S; Wadood A; Ng HL; Chen HF; Wei Z; Luo R; Zhang J
    Expert Opin Drug Discov; 2023 Mar; 18(3):315-333. PubMed ID: 36715303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allosteric Modulators of Protein-Protein Interactions (PPIs).
    Ni D; Liu N; Sheng C
    Adv Exp Med Biol; 2019; 1163():313-334. PubMed ID: 31707709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fragment-based exploration of the 14-3-3/Amot-p130 interface.
    Centorrino F; Andlovic B; Cossar P; Brunsveld L; Ottmann C
    Curr Res Struct Biol; 2022; 4():21-28. PubMed ID: 35036934
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Developing drugs for the 'undruggable'.
    Sawyer A
    Biotechniques; 2020 Oct; 69(4):239-241. PubMed ID: 33054382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Druggable protein-protein interactions--from hot spots to hot segments.
    London N; Raveh B; Schueler-Furman O
    Curr Opin Chem Biol; 2013 Dec; 17(6):952-9. PubMed ID: 24183815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strategies for targeting undruggable targets.
    Zhang G; Zhang J; Gao Y; Li Y; Li Y
    Expert Opin Drug Discov; 2022 Jan; 17(1):55-69. PubMed ID: 34455870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evolution of In Silico Strategies for Protein-Protein Interaction Drug Discovery.
    Macalino SJY; Basith S; Clavio NAB; Chang H; Kang S; Choi S
    Molecules; 2018 Aug; 23(8):. PubMed ID: 30082644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Fragment-based drug discovery: concept and aim].
    Tanaka D
    Yakugaku Zasshi; 2010 Mar; 130(3):315-23. PubMed ID: 20190516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibitors of protein-protein interactions (PPIs): an analysis of scaffold choices and buried surface area.
    Ran X; Gestwicki JE
    Curr Opin Chem Biol; 2018 Jun; 44():75-86. PubMed ID: 29908451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lessons from Hot Spot Analysis for Fragment-Based Drug Discovery.
    Hall DR; Kozakov D; Whitty A; Vajda S
    Trends Pharmacol Sci; 2015 Nov; 36(11):724-736. PubMed ID: 26538314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of physicochemical properties of protein-protein interaction modulators suggests stronger alignment with the "rule of five".
    Truong J; George A; Holien JK
    RSC Med Chem; 2021 Oct; 12(10):1731-1749. PubMed ID: 34778774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fragment-based drug discovery-the importance of high-quality molecule libraries.
    Bon M; Bilsland A; Bower J; McAulay K
    Mol Oncol; 2022 Nov; 16(21):3761-3777. PubMed ID: 35749608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting protein-protein interactions with low molecular weight and short peptide modulators: insights on disease pathways and starting points for drug discovery.
    Trisciuzzi D; Villoutreix BO; Siragusa L; Baroni M; Cruciani G; Nicolotti O
    Expert Opin Drug Discov; 2023 Jul; 18(7):737-752. PubMed ID: 37246811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AlphaSpace: Fragment-Centric Topographical Mapping To Target Protein-Protein Interaction Interfaces.
    Rooklin D; Wang C; Katigbak J; Arora PS; Zhang Y
    J Chem Inf Model; 2015 Aug; 55(8):1585-99. PubMed ID: 26225450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting druggable binding sites at the protein-protein interface.
    Fuller JC; Burgoyne NJ; Jackson RM
    Drug Discov Today; 2009 Feb; 14(3-4):155-61. PubMed ID: 19041415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical candidates modulating protein-protein interactions: The fragment-based experience.
    Valenti D; Hristeva S; Tzalis D; Ottmann C
    Eur J Med Chem; 2019 Apr; 167():76-95. PubMed ID: 30769242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural biology and drug discovery for protein-protein interactions.
    Jubb H; Higueruelo AP; Winter A; Blundell TL
    Trends Pharmacol Sci; 2012 May; 33(5):241-8. PubMed ID: 22503442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.